Last 29 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
BiomX Inc.'s quarterly P/E stands at 8.6x, down 45.0% year-over-year — suggesting improving earnings relative to price.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.29 | 8.60 | — | — | — | 15.63 | — | — | — | — | — | — | — |
| — | -45.0% | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 3427.64 | 29880.24 | 13.97 | 9962.26 | 104.40 | 83.81 | 250.24 | 232.81 | 793.95 | 496.96 | 222.25 | 115.32 | 50.63 |
| — | +35553.1% | -94.4% | +4179.1% | -86.8% | -83.1% | +12.6% | +101.9% | +1468.2% | +583.1% | +76.2% | -57.7% | -72.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | 35.68 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | 81.95 | 380.93 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -130.2% | -61.8% | -27.7% | -31.5% | -46.8% | 15.5% | 17.8% | -133.5% | -97.7% | -65.8% | -40.1% | -34.2% | -24.7% |
| — | -498.6% | -255.6% | +76.4% | +52.1% | +123.6% | +144.4% | -290.2% | -295.2% | -187.9% | -94.8% | -83.3% | -19.4% | |
| ROA | -51.9% | -28.5% | -14.4% | -17.2% | -28.1% | 7.9% | 6.0% | -32.5% | -18.9% | -21.3% | -15.5% | -14.6% | -12.1% |
| — | -462.3% | -342.3% | +47.0% | -48.7% | +137.0% | +138.4% | -122.1% | -56.5% | -73.1% | -31.8% | -31.4% | +7.7% | |
| ROIC | -305.2% | -54.1% | -39.6% | -39.3% | 62.5% | -55.0% | -158.3% | — | -152.7% | -206.4% | -97.6% | -63.6% | -46.6% |
| — | +1.6% | +75.0% | — | +140.9% | +73.4% | -62.2% | — | -228.0% | -388.4% | -162.7% | -12.2% | +64.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 46.4% YoY to 1.70x, tightening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.40 | 0.63 | 0.49 | 0.38 | 0.40 | 0.26 | 0.36 | 0.44 | 4.90 | 1.99 | 1.11 | 1.16 | 0.92 |
| — | +144.1% | +35.6% | -14.3% | -91.9% | -87.1% | -67.5% | -61.9% | +432.4% | +172.7% | +87.1% | +133.9% | +118.5% | |
| Debt / EBITDA | — | — | — | — | 0.54 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.48 | 1.70 | 2.66 | 3.35 | 2.48 | 3.17 | 4.80 | 4.40 | 1.58 | 1.98 | 2.84 | 3.23 | 4.65 |
| — | -46.4% | -44.7% | -23.8% | +57.3% | +60.0% | +68.8% | +36.2% | -66.0% | -65.2% | -61.8% | -45.3% | -23.0% | |
| Quick Ratio | 2.48 | 1.70 | 2.66 | 3.35 | 2.48 | 3.17 | 4.80 | 4.40 | 1.58 | 1.98 | 2.84 | 3.23 | 4.65 |
| — | -46.4% | -44.7% | -23.8% | +57.3% | +60.0% | +68.8% | +36.2% | -66.0% | -65.2% | -61.8% | -45.3% | -23.0% | |
| Interest Coverage | -14.01 | -1707.20 | -247.77 | -9.58 | 3337.00 | -2105.40 | -748.08 | -2.59 | -10.14 | -13.58 | -8.15 | -10.99 | -9.62 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonBiomX Inc.'s current P/E is -4.3x. The average P/E over the last 1 quarters is 8.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BiomX Inc.'s business trajectory between earnings reports.